Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an East Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial

This phase 3a randomized, double-blind, double-dummy, placebo-controlled trial assessed the efficacy and safety of once-weekly subcutaneous semaglutide 2.4 mg in East Asian adults with overweight or obesity, with or without type 2 diabetes. Participants were randomized to receive semaglutide or placebo for 68 weeks, alongside lifestyle interventions. The primary endpoint